Acta Crystallographica Section E

Structure Reports Online

ISSN 1600-5368

Michael Bolte, a* Hemmige S. Yathirajan, B. Nagaraj and P. Nagaraja

^aInstitut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Marie-Curie-Straße 11, 60439 Frankfurt/Main, Germany, and ^bDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India

Correspondence e-mail: bolte@chemie.uni-frankfurt.de

Key indicators

Single-crystal X-ray study T = 173 KMean $\sigma(\text{C-C}) = 0.002 \text{ Å}$ Disorder in main residue R factor = 0.033 wR factor = 0.087 Data-to-parameter ratio = 15.7

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

Disorder in ondansetron hydrochloride dihydrate

The structure of the title compound, 2-methyl-1-(1,2,3,9-tetrahydro-9-methyl-4-oxo-4*H*-carbazol-3-ylmethyl)-1*H*-imid-azol-3-ium chloride dihydrate, $C_{18}H_{24}N_3^+\cdot Cl^-\cdot 2H_2O$, has been reported previously by Collin, Moureau, Quintero, Vercauteren, Evrard & Durant [(1995). *J. Chem. Soc. Perkin Trans.* 2, pp. 77–84] and Chandra Mohan & Ravikumar, [(1995), *Acta Cryst.* C**51**, 2627–2629]. In both determinations, all atoms were refined as clearly ordered. In contrast to this, we present here a redetermination of this structure from new intensity data where two atoms of the cyclohexenone ring are disordered over two sites. Apart from this disorder, our results agree with the already published data.

Received 3 November 2004 Accepted 9 November 2004 Online 11 December 2004

Comment

The title compound, (I), is an anti-emetic, which has been described by Milne & Heel (1991). It is a highly selective 5-HT3 receptor antagonist (Ye *et al.*, 2001). A perspective view is shown in Fig. 1.

The structure of (I) has already been determined twice at room temperature by two different research groups (Collin et al., 1995; Chandra Mohan & Ravikumar, 1995). Both of these structures were refined as perfectly ordered. However, we have collected data at low temperature and discovered that two atoms of the cyclohexenone ring are disordered over two sites. In order to check if the crystal had undergone a phase transition upon cooling, a data set was collected on a different crystal at room temperature. This crystal showed the same disorder as the crystal investigated at low temperature. As a result, a phase transition can be ruled out. A closer look at both published ordered structures shows that the displacement ellipsoids of the atoms in question (C2 and C3 in the present structure) are elongated, which suggest disorder. Furthermore, the bond length between these atoms is significantly shortened in the two published structures (1.479 and

© 2005 International Union of Crystallography Printed in Great Britain – all rights reserved

organic papers

1.485 Å) compared with the value [1.536 (3) Å] we found in the major component. This indicates an average of two positions for the two atoms. As a result, the previous structures seem to be disordered as well, but were not refined as such. Apart from this disorder, our results agree with the already published data. Bond lengths and angles can be regarded as normal (Cambridge Structural Database, Version 1.6 plus three updates; *Mogul* Version 1.0; Allen, 2002).

Experimental

The sample of the title compound was obtained as a gift from CIPLA, India. It was used without further purification and recrystallized from methanol to give colourless blocks.

Crystal data

$C_{18}H_{20}N_3O^+\cdot Cl^-\cdot 2H_2O$	$D_x = 1.349 \text{ Mg m}^{-3}$
$M_r = 365.85$	Mo $K\alpha$ radiation
Monoclinic, $P2_1/c$	Cell parameters from 20705
a = 15.0216 (13) Å	reflections
b = 9.6464 (8) Å	$\theta = 3.7 - 27.6^{\circ}$
c = 12.6545 (10) Å	$\mu = 0.23 \text{ mm}^{-1}$
$\beta = 100.708 (6)^{\circ}$	T = 173 (2) K
$V = 1801.8 (3) \text{ Å}^3$	Block, colourless
Z = 4	$0.33 \times 0.27 \times 0.14 \text{ mm}$

Data collection

Stoe IPDS-II two-circle	4181 independent reflections
diffractometer	3172 reflections with $I > 2\sigma(I)$
ω scans	$R_{\rm int} = 0.058$
Absorption correction: multi-scan	$\theta_{\rm max} = 27.7^{\circ}$
(MULABS; Spek, 1990; Blessing,	$h = -19 \rightarrow 19$
1995)	$k = -12 \rightarrow 12$
$T_{\min} = 0.928, T_{\max} = 0.967$	$l = -16 \rightarrow 16$
24157 measured reflections	

Refinement

Refinement on F^2	H atoms treated by a mixture
$R[F^2 > 2\sigma(F^2)] = 0.033$	independent and constrained
$wR(F^2) = 0.087$	refinement
S = 0.96	$w = 1/[\sigma^2(F_o^2) + (0.0567P)^2]$
4181 reflections	where $P = (F_o^2 + 2F_c^2)/3$
267 parameters	$(\Delta/\sigma)_{\rm max} < 0.001$
	$\Delta \rho_{\text{max}} = 0.24 \text{ e Å}^{-3}$
	$\Delta \rho_{\min} = -0.21 \text{ e Å}^{-3}$

Table 1 Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	$D-\mathrm{H}$	$H \cdot \cdot \cdot A$	$D \cdot \cdot \cdot A$	$D-\mathrm{H}\cdots A$
N23−H23···O1W	0.92(2)	1.75 (2)	2.6663 (16)	178.0 (19)
$O1W-H1WB\cdots Cl1$	0.82(2)	2.32 (2)	3.1252 (14)	166 (2)
$O2W-H2WB\cdots Cl1$	0.89(3)	2.33 (3)	3.2171 (15)	175 (2)
$O1W$ $-H1WA \cdot \cdot \cdot Cl1^i$	0.85(3)	2.32 (3)	3.1334 (14)	161 (2)
O2W−H2WA···Cl1 ⁱⁱ	0.82(3)	2.41 (3)	3.2205 (15)	172 (2)

Symmetry codes: (i) -x, $y - \frac{1}{2}$, $\frac{1}{2} - z$; (ii) -x, 1 - y, -z.

The site-occupation factors of the disordered atoms refined to 0.791 (6) and 0.209 (6). In the second crystal examined at room temperature, the ratio of the site-occupation factors refined to 0.759 (9)/0.241 (9). H atoms were refined with fixed individual displacement parameters $[U_{\rm iso}({\rm H})=1.2U_{\rm eq}({\rm C}) \text{ or } 1.5U_{\rm eq}({\rm C}_{\rm methyl})]$ using a riding model, with C-H = 1.00 Å, C-H = 0.99 Å, C-H = 0.98 and 0.95 Å, for tertiary CH, secondary CH, methyl CH and




Figure 1Perspective view of the title compound, with the atom numbering. Displacement ellipsoids are drawn at the 50% probability level.

aromatic CH, respectively. The methyl groups were allowed to rotate but not to tip. H atoms bonded to O and N atoms were refined isotropically.

Data collection: *X-AREA* (Stoe & Cie, 2001); cell refinement: *X-AREA*; data reduction: *X-AREA*; program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1990); program(s) used to refine structure: *SHELXL*97 (Sheldrick, 1997); molecular graphics: *XP* in *SHELXTL-Plus* (Sheldrick, 1991); software used to prepare material for publication: *SHELXL*97 and *PLATON* (Spek, 2003).

One of the authors (HSY) thanks CIPLA, Mumbai, for a gift sample of ondansetron hydrochloride dihydrate.

References

of

```
Allen, F. H. (2002). Acta Cryst. B58, 380–388.
Blessing, R. H. (1995). Acta Cryst. A51, 33–38.
Chandra Mohan, K. & Ravikumar, K. (1995). Acta Cryst. C51, 2627–2629.
Collin, S., Moureau, F., Quintero, M. G., Vercauteren, D. P., Evrard, G. & Durant, F. (1995). J. Chem. Soc. Perkin Trans. 2, pp. 77–84.
Milne, R. J. & Heel, R. C. (1991). Drugs, 41, 574–575.
Sheldrick, G. M. (1990). Acta Cryst. A46, 467–473.
Sheldrick, G. M. (1991). SHELXTL-Plus. Release 4.1. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
Sheldrick, G. M. (1997). SHELXL97. University of Göttingen, Germany.
Spek, A. L. (2003). J. Appl. Cryst. 36, 7–12.
Stoe & Cie (1988). X-AREA. Stoe & Cie, Darmstadt, Germany.
Ye, J. H., Ponnudurai, R. & Schaefer, R. (2001). CNS Drug Rev. 7, 199–213.
```